Aidixi (disitamab vedotin) / Pfizer, RemeGen - LARVOL DELTA

Disitamab vedotin plus radiotherapy for HER2-expressing high- or very-high-risk non-muscle-invasive bladder cancer: A phase II trial (ESMO 2026) - No abstract available

P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • HER-2

Disitamab Vedotin combining with BCG intravesical instillation versus BCG in HER2 expressed high-risk NMIBC patients: a prospective, multicenter, randomised,phase 3 trial (Formula-02) (ESMO 2026) - No abstract available

Clinical • P3 data • Bladder Cancer • Oncology • HER-2

Disitamab Vedotin combining with BCG intravesical instillation in BCG-naïve, HER2 expression, very high-risk non-muscle invasive bladder cancer: a prospective, single-cohort, open-label, phase II study (Formula-03) (ESMO 2026) - No abstract available

Clinical • P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • HER-2

Perioperative disitamab vedotin with or without radiotherapy as a bladder-preserving strategy for HER2-expressing T1-T2 bladder urothelial carcinoma: A preliminary efficacy and safety analysis (ESMO 2026) - No abstract available

Clinical • Bladder Cancer • Oncology • Solid Tumor • Urothelial Cancer • HER-2

Dynamic Changes in Circulating Tumor Cells (CTCs), HER-2 Expression, and Aneuploidy Predict Treatment Response and Recurrence in Muscle-Invasive Bladder Cancer (MIBC) Receiving Neoadjuvant Disitamab Vedotin (DV) Plus Toripalimab: An Updated Analysis (ESMO 2026) - No abstract available

Circulating tumor cells • Clinical • Tumor cell • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • CTCs • HER-2

PUNCH03: Interim results from a phase II study of disitamab vedotin combined with tislelizumab and Bacillus Calmette-Guerin (BCG) in Her2-positive high-risk non-muscle-invasive bladder cancer (HR NMIBC) (ESMO 2026) - No abstract available

P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • HER-2

Induction chemotherapy followed by toripalimab, disitamab vedotin, and radiotherapy for bladder preservation in HER2-positive muscle-invasive bladder cancer (MIBC): An open-label, single-arm study (ESMO 2026) - No abstract available

Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • HER-2

Efficacy and Safety of Disitamab Vedotin Combined with Intravesical Instillation Mitomycin-C in Patients with HER2-Expressing High-Risk Non–Muscle- Invasive Bladder Cancer: A Phase II Study (ESMO 2026) - No abstract available

Clinical • P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • HER-2

Disitamab Vedotin plus PD-1 Inhibitor versus Gemcitabine-Platinum Chemotherapy and Observation as Adjuvant Therapy for High-Risk Upper Tract Urothelial Carcinoma: A Real-World Comparative Effectiveness Study (ESMO 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Oncology • Solid Tumor • Urothelial Cancer

Disitamab vedotin (RC48) and Cadonilimab (AK104) as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): preliminary results of phase Ⅱ trial (ESMO 2026) - No abstract available

Clinical • Metastases • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

Prospective Single-Arm Exploratory Study of Disitamab Vedotin Combination Regimen as Neoadjuvant Therapy for HER2-Expressing Ovarian Cancer (ESMO 2026) - No abstract available

Clinical • Oncology • Ovarian Cancer • Solid Tumor • HER-2

Clinical activity and safety of disitamab vedotin plus lenvatinib in previously treated HER2-expressing advanced biliary tract cancer: a prospective single-arm phase II study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor • HER-2

Neoadjuvant Tislelizumab plus Disitamab Vedotin for UTUC: Mid-term Results of the Phase II WUTSUP-02 Trial (ESMO 2026) - No abstract available

Clinical • P2 data • Genito-urinary Cancer • Oncology • Solid Tumor

A Phase II Multicenter Study of Neoadjuvant Disitamab Vedotin Combined with Gemcitabine in MIBC Patients with HER2 2 3+: Interim Prognostic Outcomes (ESMO 2026) - No abstract available

Clinical • P2 data • Bladder Cancer • Oncology • HER-2

Disitamab Vedotin in HER2-Expressing Locally Advanced or Metastatic Pancreatic Cancer: A Prospective, Single-Arm, Phase II Clinical Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor • HER-2

Perioperative Disitamab Vedotin plus Sintilimab and XELOX for Resectable HER2-overexpression Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study (ESMO 2026) - No abstract available

P2 data • Gastric Adenocarcinoma • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

Disitamab Vedotin (RC48)-based Therapy in Heavily Prior Treated Patients with Recurrent Ovarian Cancer: A Real-World Multicenter Study (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Oncology • Ovarian Cancer • Solid Tumor

QL1706 plus disitamab vedotin in platinum-refractory or platinum-intolerant unresectable locally advanced or metastatic penile squamous cell carcinoma: BRIGHT-01, a prospective phase II study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Penile Cancer • Squamous Cell Carcinoma

A randomized phase 3 study of disitamab vedotin (DV) versus chemotherapy (chemo) in HER2-low advanced breast cancer: overall and the liver metastasis (BCLM) subgroup results (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Disitamab vedotin combined with PD-1 inhibitors for postoperative adjuvant therapy in upper tract urothelial carcinoma: a retrospective exploratory case series. (PubMed, Front Pharmacol) - "Upper tract urothelial carcinoma (UTUC) carries a high risk of postoperative recurrence; however, the decline in renal function following radical nephroureterectomy often limits the use of cisplatin-based chemotherapy. Treatment-related adverse events (TRAEs) of any grade and Grade ≥3 TRAEs occurred in four and two patients, respectively; no Grade 4-5 adverse events or treatment-related deaths were observed. These results provided a preliminary description of the practical feasibility and observed safety of this regimen in a specific cohort of postoperative UTUC patients; however, given the very small sample size and the lack of a control group, no conclusions regarding therapeutic efficacy could be drawn, and further prospective studies are required for evaluation."

IO biomarker • Journal • Retrospective data • Oncology • Solid Tumor • Urothelial Cancer • HER-2 • PD-L1

Disitamab Vedotin in locally advanced or metastatic extramammary Paget's disease with HER2 high expression: a prospective, single-arm phase II trials (Formula-10) (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Metastases • P2 data • Melanoma • Oncology • Skin Cancer • Solid Tumor • HER-2

Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial. (PubMed, Nat Commun) - P2/3 | "Based on the phase 2 results, the phase 3 stage was initiated to evaluate disitamab vedotin (DV) versus lapatinib plus capecitabine (L + C) in patients with HER2-positive BCLM who were previously treated with trastuzumab and taxanes. Similar incidences of grade ≥3 treatment-related adverse events were reported with DV versus L + C (37.7% vs 36.0%). The present findings support DV as a treatment option for HER2-positive BCLM following trastuzumab and taxane therapy."

Clinical • Journal • P2/3 data • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Efficacy of disitamab vedotin, AK104, and bevacizumab in HER2-positive recurrent ovarian clear cell cancer: Phase II DAB-OCCC trial (ESMO 2025) - P2 | "(%) Taxene 15 (100%) PARPi 4 (27%) Bevacizumab 11 (73%) Immune Therapy 1 (7%) Conclusions The combination of DV, AK104, and bevacizumab demonstrated clinically meaningful antitumor activity and a manageable safety profile in HER2-positive, PRR OCCC. This phase 2 trial met its pre-specified efficacy threshold in the first stage."

Clinical • IO biomarker • P2 data • Oncology • Ovarian Cancer • Ovarian Clear Cell Cancer • HER-2 • PD-L1

REFRACTORY HICCUPS AND SEVERE HYPONATREMIA AS THE INITIAL PRESENTATION OF TISLELIZUMAB-INDUCED ISOLATED ADRENOCORTICOTROPIC HORMONE DEFICIENCY: A CASE REPORT (UEGW 2026) - "Five months earlier, he'd had a left nephroureterectomy, followed by adjuvant therapy with disitamab vedotin (120 mg) and tislelizumab (200 mg). His sodium was brought up gradually over 72 hours. He was switched to oral maintenance hydrocortisone (40 mg in the morning, 20 mg in the evening) and discharged in stable condition."

Case report • Clinical • Cardiovascular • Endocrine Disorders • Heart Failure • Hypertension • Nephrology • Renal Disease • Solid Tumor • Urothelial Cancer

Clinical Outcomes of Disitamab Vedotin in HER2-Expressing Advanced Gastric and Gastroesophageal Junction Cancers: A Systematic Review and Meta-Analysis (ACG 2026) - "Six studies comprising eight cohorts (n=363) were included. The pooled ORR was 27.0% (95% CI 19.0-35.0), with higher responses observed in combination therapy versus monotherapy (41.8% compared with 20.4%). Estimated pooled median PFS and OS were 4.72 months (95% CI 3.80-5.64) and 9.68 months (95% CI 7.32-12.04), respectively."

Clinical data • Metastases • Retrospective data • Review • Gastric Cancer • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • HER-2